At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Find the latest Arrowhead Pharmaceuticals, Inc. (ARWR) stock quote, history, news and other vital information to help you with your stock trading and investing.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

PASADENA, Calif., September 29, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host an R&D webinar on Wednesday, October 14, 2026, at 11:30 AM PDT that will focus on investigational therapy ARO-MAPT and Arrowhead’s central nervous system (CNS) pipeline. The webinar will feature a presentation from Adam Boxer, M.D., Ph.D., Endowed Professor in Memory and Aging in the Department of Neurology at the University of California, San Francisco (UCSF), where he directs t

PASADENA, Calif., September 29, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host an R&D webinar on Wednesday, October 14, 2026, at 11:30 AM PDT that will focus on investigational therapy ARO-MAPT and Arrowhead’s central nervous system (CNS) pipeline. The webinar will feature a presentation from Adam Boxer, M.D., Ph.D., Endowed Professor in Memory and Aging in the Department of Neurology at the University of California, San Francisco (UCSF), where he directs t

En Yahoo Finance, obtienes cotizaciones de acciones gratuitas, noticias actualizadas, recursos de gestión de carteras, datos de mercados internacionales, interacción social y tasas hipotecarias que te ayudarán a gestionar tu vida financiera.

Goldman sees biotech’s recent gains holding up despite macro pressures, supported by deal activity, clinical progress, and a more favorable regulatory backdrop.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Arrowhead Pharmaceuticals (ARWR) is down 7.3% today. Here is some analysis on what might have caused

Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives outlined early clinical data for its RNA interference dimer program, progress in the launch of plozasiran and plans for central nervous system and metabolic disease candidates during the Morgan Stanley Global Healthcare Conference. Early Dimer Data

Arrowhead Pharmaceuticals (NASDAQ:ARWR) is expanding its commercial and clinical footprint around RNA interference therapies, with its recently launched triglyceride-lowering treatment REDEMPLO and several pipeline programs targeting cardiometabolic disease, obesity and central nervous system disord

Arrowhead Pharmaceuticals (ARWR) has drawn fresh attention after reporting interim Phase 1/2a data for ARO-DIMER-PA, its dual RNA interference candidate targeting atherosclerotic cardiovascular disease due to mixed hyperlipidemia. Arrowhead Pharmaceuticals has been volatile around the interim ARO-DIMER-PA update, with the share price down 19.76% over the past week and 25.65% over the past month. However, the 1 year total shareholder return of 116.62% and 3 year total shareholder return of...